Current Report · Items 7.01, 9.01 · 8-K

Accendra Health, Inc.

ACHNYSEEQUITYCurrent

Regulation FD Disclosure

Filed Aug 17, 2026Accepted Aug 17, 2026, 6:42 AM EDTCIK 75252Accession 0001104659-26-097517

Company context

Accendra Health, Inc. (NYSE: ACH) is a leading nationwide provider of products, technology, and services that support health beyond the hospital for millions of people each year. We connect patients, providers, and insurers, delivering innovative solutions that help promote better health outcomes and improve quality of life for people living with chronic, complex health conditions. Backed by the industry-leading expertise of our Apria and Byram brands, Accendra Health is reimagining the future of home-based care. To learn more about our broad portfolio of essentials for diabetes, sleep health, wound care, respiratory care, urology, and ostomy, visit www.accendrahealth.com.

Current securities

ACHNYSE · EQUITY · Current

Recent company filings

Disclosure sections

Items 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On August 17, 2026, the Company issued a press release providing updates on its capital allocation plans, including the Company’s decision not to implement an at-the-market equity issuance program, the opportunistic sale of two non-core assets and the status of the Company’s Chief Executive Officer succession process. The Company is furnishing the press release attached hereto as Exhibit 99.1 pursuant to Item 7.01 of Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such a filing.

Filed exhibits (1)

EX-99.1 (by filename) tm2622667d5_ex99-1.htm

EX-99.1 2 tm2622667d5_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans RICHMOND, VA - August 17, 2026 - Accendra Health (the “Company”) is providing an update on its capital allocation plans and the timeline for the replacement of its chief executive officer. Given recent market conditions, the Company has determined that it is in the best interest of stakeholders not to put in place an at-the-market issuance program. The program was intended to allow the Company to opportunistically issue modest amounts of equity over time, with the proceeds to be used to reduce outstanding indebtedness, including debt trading at discounts to par value. The program was never intended as a source of liquidity for the Company. Not implementing the program will have no impact on the Company’s results of operations or published guidance. In addition, with increasing cash collections and strengthening progress in resolving payor collection issues, the Company remains confident in its liquidity position. The Company was undrawn on its $300 million revolving credit facility at the end of the second quarter and does not expect to re…

Open exhibit ↗

Get the free weekly BCS email.